TKT and cancer: The relevance of addressing sex as a covariate strikes hard at the current pharmacotherapy practice and management of TK inhibitors (Lankheet et al., 2014a,b) owing to the polypharmacy scenario of cancer patients (Leblanc et al., 2015): several preclinical DDI studies of sunitinib with selected NSAIDs, have shown that the DDI effects on plasma and tissue were different in male and female mice.